![]() |
Trials |
An open-label, multicenter, dose-escalation phase 1b study to investigate the safety, pharmacokinetics, phamacodynamics, and therapeutic activity of RO7009789 (CD40 agonist) in combination with MPDL3280A (anti-PD-L1) in patients with locally advancedand/oCancer type: Solide tumores Phase: I Principal Investigator: Lassen Ulrik Country: DK Keywords: Denmark, Rigshospitalet Status: Open for inclusion Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02304393?term=BP29392&rank=1 |